NCT00662597 2020-12-24
ATRACT-1
Novartis
Phase 3 Terminated
Clinical Trials
12 trialsNCT00738387 2020-12-24
ATTRACT-2
Novartis
Phase 3 Terminated
NCT00674102 2020-12-09
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
Novartis
Phase 1 Completed
NCT01240642 2020-12-09
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
Novartis
Phase 1 Terminated
NCT01278758 2020-12-09
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Novartis
Phase 1 Terminated
NCT01278849 2020-12-09
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
Novartis
Phase 1 Terminated
NCT01285453 2020-12-09
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
Novartis
Phase 1 Completed
NCT01299701 2017-02-14
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
Novartis
Phase 1 Terminated
NCT01290380 2011-09-02
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
Novartis
Phase 1 Terminated
NCT01299415 2011-09-02
Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor
Novartis
Phase 1 Terminated
NCT00856336 2009-03-05
DART
Antisoma Research
Phase 1 Completed
NCT00111618 2009-01-30
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Antisoma Research
Phase 2 Completed